COMPANY

Trellis Bioscience

HQ: Redwood City, CA source · trellisbio.com ↗ · West Coast

Location: Redwood City, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: influenza rabies Prosthetic Joint Infections of Hip Prosthetic Joint Infections of Knee Prosthetic Joint Infection Chronic Rhinosinusitis With Nasal Polyps bacterial pneumonia TRL1068, a human monoclonal antibody TRL1068 (calpurbatug), a human monoclonal antibody TRL1068

5Trials (company is sponsor)38NIH grants

Funding and NIH signals

SEC Form D raise Raised $6.09M (Form D filed May 15, 2026). SEC Form D 0000929638-26-001870 (May 15, 2026)
Evidence (1 event)
- May 15, 2026 · SEC Form D 0000929638-26-001870
  Name of Issuer: Trellis Bioscience, Inc.; CIK: 1162015; Address: Redwood City, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Other (Series C Interests); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 6093000; Federal exemptions: 06b
NIH award NIH awarded $999K (SBIR Phase II 4U44AI183920-02, extension, notice Aug 12, 2026); 2 NIH awards totaling $2M in the last 12 months. NIH RePORTER 4U44AI183920-02 (Aug 12, 2026)
Evidence (2 events)
- Aug 12, 2026 · NIH RePORTER 4U44AI183920-02
  Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 4U44AI183920-02; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 998879; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bacterial Pneumonia Therapeutic Antibody Safety Trial; Organization type: Domestic For-Profits
- Jul 29, 2026 · NIH RePORTER 1SB1AI191674-01
  Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 1SB1AI191674-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 999759; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Human Antibody for Acute Infection Treatment of RSV; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2026-10 Trial start Phase 1: Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers source ↗
Aug 12, 2026 Grant Government grant — SBIR: $998,879 (annual award, as published), announced Aug 12, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 29, 2026 Grant Government grant — SBIR: $999,759 (annual award, as published), announced Jul 29, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 8, 2025 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection source ↗
2024-01 Trial start Phase 1: Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis source ↗
Sep 14, 2023 Trial start Phase 1: Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers source ↗
Feb 8, 2021 Trial start Phase 1: Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers · NCT07644195
2027-04 (ESTIMATED) · Phase 2 · Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection · NCT06621251

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Aug 12, 2026 Government grant — SBIR: $998,879 (annual award, as published), announced Aug 12, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 29, 2026 Government grant — SBIR: $999,759 (annual award, as published), announced Jul 29, 2026. Agency: NIH/NIAID. Source: government award database. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT05408091	Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers	Phase 1	Completed	Sep 14, 2023	Dec 23, 2024 (actual)
NCT07644195	Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers	Phase 1	Not yet recruiting	2026-10	2026-12 (estimated)
NCT06621251	Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection	Phase 2	Active, not recruiting	Apr 8, 2025	2027-04 (estimated)
NCT04763759	Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections	Phase 1	Completed	Feb 8, 2021	Mar 13, 2024 (actual)
NCT05355207	Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis	Phase 1	Unknown status (ClinicalTrials.gov)	2024-01	2025-01 (estimated)

NIH awards 38

Annual award amounts. Total $29.8M.

Jul 18, 2024 NIH award 1U44AI183920-01 FY2024: $297,917 awarded for that fiscal year; activity U44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Bacterial Pneumonia Therape source ↗
Jun 28, 2024 NIH award 5U44AI152970-03 FY2024: $998,144 awarded for that fiscal year; activity U44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. HCMV Therapeutic Antibody S source ↗
Jul 20, 2023 NIH award 4U44AI152970-02 FY2023: $998,144 awarded for that fiscal year; activity U44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. HCMV Therapeutic Antibody S source ↗
Aug 19, 2022 NIH award 5R44AI150143-03 FY2022: $989,273 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Biofilm disrupting antibody source ↗
Jan 15, 2022 NIH award 5R44AI106077-07 FY2022: $999,820 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Aug 2, 2021 NIH award 5R44AI150143-02 FY2021: $990,949 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Biofilm disrupting antibody source ↗
Feb 1, 2021 NIH award 5R44AI106077-06 FY2021: $999,451 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Dec 23, 2020 NIH award 5R44AI122360-05 FY2021: $997,704 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for RS source ↗
Sep 1, 2020 NIH award 1R44AI150143-01 FY2020: $999,192 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Biofilm disrupting antibody source ↗
Jun 26, 2020 NIH award 1U44AI152970-01 FY2020: $299,667 awarded for that fiscal year; activity U44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. HCMV Therapeutic Antibody S source ↗
Feb 6, 2020 NIH award 2R44AI106077-05 FY2020: $999,214 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Nov 29, 2019 NIH award 5R44AI122360-04 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for source ↗
Jun 11, 2019 NIH award 5SB1AI120425-05 FY2019: $999,961 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Apr 24, 2019 NIH award 5SB1AI102396-08 FY2019: $999,425 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for CM source ↗
Dec 11, 2018 NIH award 2R44AI122360-03 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for source ↗
Jun 22, 2018 NIH award 5SB1AI120425-04 FY2018: $999,953 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Apr 16, 2018 NIH award 5SB1AI102396-07 FY2018: $997,600 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for CM source ↗
Jul 26, 2017 NIH award 2SB1AI120425-03 FY2017: $999,953 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Jun 14, 2017 NIH award 5R44AI106077-04 FY2017: $981,301 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Apr 27, 2017 NIH award 2SB1AI102396-06 FY2017: $999,000 awarded for that fiscal year; activity SB1 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibody for CM source ↗
Jan 10, 2017 NIH award 5R44AI122360-02 FY2017: $1,499,589 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic antibody for source ↗
Jun 30, 2016 NIH award 2R44AI120425-02 FY2016: $999,628 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Jun 8, 2016 NIH award 5R44AI106077-03 FY2016: $987,301 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Jan 31, 2016 NIH award 1R44AI122360-01 FY2016: $1,268,751 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic antibody for source ↗
Jun 25, 2015 NIH award 1R41AI120425-01 FY2015: $224,946 awarded for that fiscal year; activity R41 (STTR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Jun 17, 2015 NIH award 4R44AI106077-02 FY2015: $941,551 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therapeu source ↗
Jan 15, 2015 NIH award 5R44AI102396-04 FY2015: $990,877 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Jun 25, 2014 NIH award 1R44AI106077-01A1 FY2014: $298,735 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Strain-Independent Therap source ↗
Jan 14, 2014 NIH award 5R44AI102396-03 FY2014: $990,935 awarded for that fiscal year; activity R44 (SBIR); PI KAUVAR, LAWRENCE MICHAEL; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗
Feb 13, 2013 NIH award 4R44AI102396-02 FY2013: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI USINGER, WILLIAM ROBERT; recipient as written: TRELLIS BIOSCIENCE, INC., Redwood City, CA. Therapeutic Antibodies for source ↗